Globenewswire·2025-11-08 15:41Core Insights - Acoramidis has shown significant clinical benefits in reducing all-cause mortality in patients with variant ATTR-CM, particularly in the V142I subpopulation, with a reported 69% reduction in mortality through Month 30 and Month 42 [1][3][4] - The study highlights the importance of early diagnosis and treatment for patients with the V142I variant, who have historically faced challenges in accessing care [2] - The findings reflect advancements in precision medicine and equity in cardiovascular care, emphasizing the need for continued research and development in this area [2] Summary by Sections Clinical Study Results - The ATTRibute-CM study demonstrated a 59% risk reduction in all-cause mortality (ACM) in the overall variant population at Month 42 compared to placebo [3] - In the V142I subpopulation, there was a 69% risk reduction in ACM through Month 30 and Month 42 [3][4] - Acoramidis also showed improvements in functional capacity, with a least-squares mean difference of 87 meters in the 6-minute walk test and a 20-point difference in the Kansas City Cardiomyopathy Questionnaire score through Month 30 [4] Patient Population Insights - The V142I variant affects 3-4% of the U.S. Black population, highlighting a significant unmet need for effective treatments in this demographic [1] - The study's results are particularly meaningful for patients with variant ATTR-CM, who have limited access to early diagnosis and treatment options [2] Regulatory and Market Information - Acoramidis is approved as Attruby® by the U.S. FDA and as BEYONTTRA® by the European Medicines Agency and other regulatory bodies, indicating its recognized efficacy in stabilizing transthyretin [6][8] - Future data on the benefits of Attruby for ATTR-CM patients is anticipated to be presented at upcoming medical meetings [7] Safety and Adverse Reactions - Adverse reactions reported with Attruby included diarrhea (11.6% vs 7.6% for placebo) and upper abdominal pain (5.5% vs 1.4% for placebo), with most being mild and resolving without discontinuation [9]